BioWorld Asia

Nov. 19, 2003

Pfizer Stalls Celltech Deal, Wants Bigger Profit Share

Celltech Group plc said partner Pfizer Inc. has decided to delay development of the rheumatoid arthritis drug CDP 870, thereby stalling the potential launch for at least one year, and wants to renegotiate the terms of the companies' profit-sharing agreement. (BioWorld International) Read More

Galapagos Genomics, Wyeth Enter $40M Osteoporosis Deal

New Mouse Model Could Unlock Mystery Of Autoimmune Disease

Lorantis' £25M In Third Round Gives It Funds For Four Years

Stem Cell Research Funding Still A Source Of Debate In EU

Abbott Pulls Out Of Diabetes Collaboration With Karo Bio

Opening European IPO Window Tantalizes Companies, Investors

UK Plans To Hold Position As Europe's Best Biotech Country

European Commission Reports Biotechnology Research Plans

Cellectis Signs Fermentas To Manufacturing Deal For I-Sce1

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for July 23, 2026.

To viral or not to viral: In vivo CAR T debates delivery tech

BioWorld

The field of cell and gene therapy is moving toward a new phase of scalability and clinical durability, with in vivo chimeric antigen receptor (CAR) T-cell...

News in brief

BioWorld Asia

BioWorld Asia briefs for July 21, 2026

Tree in the shape of human head losing leaves

KBN-2201 reverses key features of Alzheimer’s in mice

BioWorld Science

Researchers from Ajou University School of Medicine reported the preclinical efficacy of KBN-2201 in a mouse model of late-stage Alzheimer’s disease.

Click chemistry drug bound to pancreatic cancer cells from mice

In vivo click ADCs could address tumor heterogeneity

BioWorld

Researchers at Washington University in St. Louis have used click chemistry to link a second antibody to a pre-existing antibody-drug conjugate (ADC) in vivo. In...